Magnesium isoglycyrrhizinate suppresses bladder cancer progression by modulating the miR-26b/Nox4 axis

References

• Martinez Rodriguez RH, Buisan Rueda O, Ibarz L. Bladder cancer: present and future. Med Clin. 2017;149(10):449–455.
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.
   PubMed Web of Science ®Google Scholar
• Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):177–189. vii.
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–475.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Han J, Wang JZ, Yang X, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18(1):110.
   PubMed Web of Science ®Google Scholar
• Del Ben M, Polimeni L, Baratta F, et al. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol. 2017;83(1):88–95.
   PubMed Web of Science ®Google Scholar
• Huang X, Qin J, Lu S. Magnesium isoglycyrrhizinate protects hepatic L02 cells from ischemia/reperfusion induced injury. Int J Clin Exp Pathol. 2014;7(8):4755–4764.
   PubMed Web of Science ®Google Scholar
• Zheng J, Wu G, Hu GX, et al. Protective effects against and potential mechanisms underlying the effect of magnesium isoglycyrrhizinate in hypoxia-reoxygenation injury in rat liver cells. Genet Mol Res: GMR. 2015;14(4):15453–15461.
   PubMed Web of Science ®Google Scholar
• Yan Y, Mo Y, Zhang D. Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin J Hepatol. 2015;23(3):204–208
   PubMedGoogle Scholar
• Chen KJ, Chen WY, Chen X, et al. Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. Eur J Drug Metab Pharmacokinet. 2014;39(1):25–31.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Tang Z, Zhang W, et al. Magnesium isoglycyrrhizinate protects against renal‑ischemia‑reperfusion injury in a rat model via anti‑inflammation, anti‑oxidation and anti‑apoptosis. Mol Med Rep. 2017;16(3):3627–3633.
   PubMed Web of Science ®Google Scholar
• Ma D, Zhang J, Zhang Y, et al. Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway in mice. Int Immunopharmacol. 2018;55:237–244.
   PubMed Web of Science ®Google Scholar
• Li TS, Chen L, Wang SC, et al. Magnesium isoglycyrrhizinate ameliorates fructose-induced podocyte apoptosis through downregulation of miR-193a to increase WT1. Biochem Pharmacol. 2019;166:139–152.
   PubMed Web of Science ®Google Scholar
• Tang CT, Gao YJ, Ge ZZ. NOX4, a new genetic target for anti-cancer therapy in digestive system cancer. J Dig Dis. 2018;19(10):578–585.
   PubMed Web of Science ®Google Scholar
• Zeng C, Wu Q, Wang J, et al. NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells. Free Radic Biol Med. 2016;101:236–248.
   PubMed Web of Science ®Google Scholar
• Tang CT, Lin XL, Wu S, et al. NOX4-driven ROS formation regulates proliferation and apoptosis of gastric cancer cells through the GLI1 pathway. Cell Signal. 2018;46:52–63.
   PubMed Web of Science ®Google Scholar
• Du S, Miao J, Lu X, et al. NADPH oxidase 4 is correlated with gastric cancer progression and predicts a poor prognosis. Am J Transl Res. 2019;11(6):3518–3530.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Q, Shan Z, et al. The protective effect and mechanism of catalpol on high glucose-induced podocyte injury. BMC Complement Altern Med. 2019;19(1):244.
   PubMed Web of Science ®Google Scholar
• Rius J, Guma M, Schachtrup C, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453(7196):807–811.
   PubMed Web of Science ®Google Scholar
• van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J. 2008;412(3):477–484.
   PubMed Web of Science ®Google Scholar
• Shimada K, Fujii T, Anai S, et al. ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder. BMC Urol. 2011;11(1):22.
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207.
   PubMed Web of Science ®Google Scholar
• Sugita S, Yoshino H, Yonemori M, et al. Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer. Int J Oncol. 2019;54(6):2222–2236.
   PubMed Web of Science ®Google Scholar
• Yan D, Dong W, He Q, et al. Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation. EBioMedicine. 2019;48:316–331.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang D, Lv J, et al. MiR-125a-5p suppresses bladder cancer progression through targeting FUT4. Biomed Pharmacothe. 2018;108:1039–1047.
   PubMed Web of Science ®Google Scholar
• Lu JJ, Yang WM, Li F, et al. Tunneling nanotubes mediated microRNA-155 intercellular transportation promotes bladder cancer cells’ invasive and proliferative capacity. Int J Nanomedicine. 2019;14:9731–9743.
   PubMed Web of Science ®Google Scholar
• Hou G, Xu W, Jin Y, et al. MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D. Biochem Biophys Res Commun. 2019;519(4):747–753.
   PubMed Web of Science ®Google Scholar
• Wang JR, Liu B, Zhou L, et al. MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer. Cancer Biomarkers. 2019;24(2):159–172.
   PubMed Web of Science ®Google Scholar
• Cao J, Wang Q, Wu G, et al. miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a. Int Urol Nephrol. 2018;50(10):1811–1819.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Seki N, Matsushita R, et al. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. Br J Cancer. 2016;115(3):354–363.
   PubMed Web of Science ®Google Scholar
• Wang LS, Chen SJ, Zhang JF, et al. Anti-proliferative potential of Glucosamine in renal cancer cells via inducing cell cycle arrest at G0/G1 phase. BMC Urol. 2017;17(1):38.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiang W, Wang M, et al. Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101. Br J Pharmacol. 2014;171(3):618–635.
   PubMed Web of Science ®Google Scholar
• Lu Q, Liu T, Feng H, et al. Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN. Molecular Cancer. 2019;18(1):111.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Cao W, Zhao Y, Wang L, et al. Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression. Cancer Biomarkers. 2019;25(1):101–113.
   PubMed Web of Science ®Google Scholar
• Farling KB. Bladder cancer: risk factors, diagnosis, and management. Nurse Pract. 2017;42(3):26–33.
   PubMed Web of Science ®Google Scholar
• Smith AB, Jaeger B, Pinheiro LC, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121(4):549–557.
   PubMed Web of Science ®Google Scholar
• Smith AB. Recent developments in the management of bladder cancer: introduction. Urol Oncol. 2018;36(3):95–96.
   PubMed Web of Science ®Google Scholar
• Xia Y, Kang TW, Jung YD, et al. Sulforaphane inhibits nonmuscle invasive bladder cancer cells proliferation through suppression of HIF-1α-Mediated glycolysis in hypoxia. J Agric Food Chem. 2019;67(28):7844–7854.
   PubMed Web of Science ®Google Scholar
• Inoue K. 5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer. Int J Urol. 2017;24(2):97–101.
   PubMed Web of Science ®Google Scholar
• Vallianou NG, Evangelopoulos A, Schizas N, et al. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 2015;35(2):645–651.
   PubMed Web of Science ®Google Scholar
• Makarević J, Rutz J, Juengel E, et al. Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2. PloS One. 2014;9(8):e105590.
   PubMed Web of Science ®Google Scholar
• Wang B, Lu FY, Shi RH, et al. MiR-26b regulates 5-FU-resistance in human colorectal cancer via down-regulation of Pgp. Am J Cancer Res. 2018;8(12):2518–2527.
   PubMed Web of Science ®Google Scholar
• Li J, Liang Y, Lv H, et al. miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway. Gene. 2017;625:1–9.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yang F. [MiR-26b regulates invasion and migration of lung cancer cells through targeting hENT1 depending on RhoA/ROCK-1 pathway]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Med sci. 2017;42(7):755–761.
   PubMedGoogle Scholar
• Meitzler JL, Makhlouf HR, Antony S, et al. Decoding NADPH oxidase 4 expression in human tumors. Redox Biol. 2017;13:182–195.
   PubMed Web of Science ®Google Scholar
• Kim EY, Seo JM, Kim C, et al. BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species-linked pathway. Free Radic Biol Med. 2010;49(6):1072–1081.
   PubMed Web of Science ®Google Scholar
• Seo JM, Cho KJ, Kim EY, et al. Up-regulation of BLT2 is critical for the survival of bladder cancer cells. Exp Mol Med. 2011;43(3):129–137.
   PubMed Web of Science ®Google Scholar
• Adams JM, Difazio LT, Rolandelli RH, et al. HIF-1: a key mediator in hypoxia. Acta Physiol Hung. 2009;96(1):19–28.
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang Z, Zhang M, et al. HIF-1α promotes ZEB1 expression and EMT in a human bladder cancer lung metastasis animal model. Oncol Lett. 2018;15(3):3482–3489.
   PubMed Web of Science ®Google Scholar
• Ł P F, Pihowicz P, Koperski Ł, et al. HIF-1α expression is inversely associated with tumor stage, grade and microvessel density in urothelial bladder carcinoma. Pol J Pathol off J Pol Soc Pathol. 2018;69(4):395–404
   PubMed Web of Science ®Google Scholar
• Sun Y, Guan Z, Liang L, et al. HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer. Oncol Rep. 2016;35(3):1549–1556.
   PubMed Web of Science ®Google Scholar